The Tumor Microenvironment of Pancreatic Cancer

doi:10.3390/cancers12103076

Editorial

. 2020 Oct 21;12(10):3076.

doi: 10.3390/cancers12103076.

The Tumor Microenvironment of Pancreatic Cancer

Eva Karamitopoulou¹

Affiliations

PMID: 33096881
PMCID: PMC7589160
DOI: 10.3390/cancers12103076

Editorial

The Tumor Microenvironment of Pancreatic Cancer

Eva Karamitopoulou. Cancers (Basel). 2020.

. 2020 Oct 21;12(10):3076.

doi: 10.3390/cancers12103076.

Author

Eva Karamitopoulou¹

Affiliation

¹ Pancreatic Cancer Research Group, Institute of Pathology University of Bern, CH-3008 Bern, Switzerland.

PMID: 33096881
PMCID: PMC7589160
DOI: 10.3390/cancers12103076

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis along with rising incidence rates and will be responsible for many cancer deaths in the future [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

**Figure 1**
(A): Pancreatic cancer from a long-term survivor (i.e., overall survival >60 months) with a «hot» tumor microenvironment, dominated by CD8+ cytotoxic tumor infiltrating lymphocytes (multiplex immunofluorescence ×400); (B): pancreatic cancer from a short-term survivor (overall survival <12 months) with an immunosuppressive tumor microenvironment poor in CD68+ tumor infiltrating lymphocytes and dominated by CD68+ tumor associated macrophages and FOXP3+ T regulatory cells (multiplex immunofluorescence ×400).

See this image and copyright information in PMC

Cited by

Current and Future Therapies for Pancreatic Ductal Adenocarcinoma.
Sally Á, McGowan R, Finn K, Moran BM. Sally Á, et al. Cancers (Basel). 2022 May 13;14(10):2417. doi: 10.3390/cancers14102417. Cancers (Basel). 2022. PMID: 35626020 Free PMC article. Review.
Dualistic role of ZEB1 and ZEB2 in tumor progression.
Parfenyev SE, Daks AA, Shuvalov OY, Fedorova OA, Pestov NB, Korneenko TV, Barlev NA. Parfenyev SE, et al. Biol Direct. 2025 Mar 20;20(1):32. doi: 10.1186/s13062-025-00604-3. Biol Direct. 2025. PMID: 40114235 Free PMC article. Review.
Potential Prognostic Biomarkers of OSBPL Family Genes in Patients with Pancreatic Ductal Adenocarcinoma.
Chou CW, Hsieh YH, Ku SC, Shen WJ, Anuraga G, Khoa Ta HD, Lee KH, Lee YC, Lin CH, Wang CY, Wang WJ. Chou CW, et al. Biomedicines. 2021 Nov 3;9(11):1601. doi: 10.3390/biomedicines9111601. Biomedicines. 2021. PMID: 34829830 Free PMC article.
Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth.
Shaji SG, Patel P, Mamani UF, Guo Y, Koirala S, Lin CY, Alahmari M, Omoscharka E, Cheng K. Shaji SG, et al. Int J Nanomedicine. 2024 Aug 27;19:8769-8778. doi: 10.2147/IJN.S462213. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39220196 Free PMC article.
Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis.
Zhao JF, Zou FL, Zhu JF, Huang C, Bu FQ, Zhu ZM, Yuan RF. Zhao JF, et al. Front Pharmacol. 2022 Oct 18;13:1025618. doi: 10.3389/fphar.2022.1025618. eCollection 2022. Front Pharmacol. 2022. PMID: 36330100 Free PMC article.

See all "Cited by" articles

References

1. Kamisawa T., Wood L.D., Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85. doi: 10.1016/S0140-6736(16)00141-0. - DOI - PubMed
1. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. doi: 10.1158/0008-5472.CAN-14-0155. - DOI - PubMed
1. Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014;371:2140–2141. doi: 10.1056/NEJMra1404198. - DOI - PubMed
1. Serrano P.E., Cleary S.P., Dhani N., Kim P.T., Greig P.D., Leung K., Moulton C.A., Gallinger S., Wei A.C. Improved long-term outcomes after resection of pancreatic adenocarcinoma: A comparison between two time periods. Ann. Surg. Oncol. 2015;22:1160–1167. doi: 10.1245/s10434-014-4196-2. - DOI - PubMed
1. Bahra M., Pratschke J., Klein F., Neuhaus P., Boas-Knoop S., Puhl G., Denecke T., Pullankavumkal J.R., Sinn M., Riess H., et al. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Pancreas. 2015;44:930–936. doi: 10.1097/MPA.0000000000000365. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Kamisawa T., Wood L.D., Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85. doi: 10.1016/S0140-6736(16)00141-0. - DOI - PubMed

[2] Kamisawa T., Wood L.D., Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85. doi: 10.1016/S0140-6736(16)00141-0. - DOI - PubMed

[3] Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. doi: 10.1158/0008-5472.CAN-14-0155. - DOI - PubMed

[4] Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. doi: 10.1158/0008-5472.CAN-14-0155. - DOI - PubMed

[5] Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014;371:2140–2141. doi: 10.1056/NEJMra1404198. - DOI - PubMed

[6] Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 2014;371:2140–2141. doi: 10.1056/NEJMra1404198. - DOI - PubMed

[7] Serrano P.E., Cleary S.P., Dhani N., Kim P.T., Greig P.D., Leung K., Moulton C.A., Gallinger S., Wei A.C. Improved long-term outcomes after resection of pancreatic adenocarcinoma: A comparison between two time periods. Ann. Surg. Oncol. 2015;22:1160–1167. doi: 10.1245/s10434-014-4196-2. - DOI - PubMed

[8] Serrano P.E., Cleary S.P., Dhani N., Kim P.T., Greig P.D., Leung K., Moulton C.A., Gallinger S., Wei A.C. Improved long-term outcomes after resection of pancreatic adenocarcinoma: A comparison between two time periods. Ann. Surg. Oncol. 2015;22:1160–1167. doi: 10.1245/s10434-014-4196-2. - DOI - PubMed

[9] Bahra M., Pratschke J., Klein F., Neuhaus P., Boas-Knoop S., Puhl G., Denecke T., Pullankavumkal J.R., Sinn M., Riess H., et al. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Pancreas. 2015;44:930–936. doi: 10.1097/MPA.0000000000000365. - DOI - PubMed

[10] Bahra M., Pratschke J., Klein F., Neuhaus P., Boas-Knoop S., Puhl G., Denecke T., Pullankavumkal J.R., Sinn M., Riess H., et al. Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Pancreas. 2015;44:930–936. doi: 10.1097/MPA.0000000000000365. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The Tumor Microenvironment of Pancreatic Cancer

Affiliation

The Tumor Microenvironment of Pancreatic Cancer

Author

Affiliation

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources